Figure 3.
Monotherapy and combination therapy of CVV and anti-PD-1 and their therapeutic efficacy. (a) CT26 tumor burden in Balb/c mice after combination therapy. CT26 cells (5 × 106 cells/100 µL of 1X PBS) were used to induce subcutaneous tumors in the left flank of Balb/c mice. Tumor burden was monitored twice weekly. When the tumor volume reached >100 mm3, treatment was started (solid lines: responders, dashed lines: nonresponders). (b) On the basis of the tumor burden, mice were categorized as responders or nonresponders. Tumor volume in responders. * p < 0.05; ** p < 0.01; *** p < 0.001. CVV, cancer-favoring oncolytic vaccinia virus; PD-1, programmed cell death protein-1; PBS, phosphate-buffered saline; D1, day 1; D8, day 8; D15, day 15; D22, day 22; D29, day 29; D36, day 36; D40, day 40.